Earnings Call · Q4 FY2022·2023-03-02

Q4 22EPS -7.69%·Rev n/aQ3 22EPS +11.11%·Rev n/aQ2 22EPS +13.33%·Rev n/aQ1 22EPS +30.00%·Rev n/a⚠ consensus missing

Arbutus Biopharma Corp ABUS

Lisa Caperelli — Executive team member

William Collier — President and Chief Executive Officer

Michael Sofia — Research team member / Scientist

David Hastings — Chief Financial Officer

0.0%1d on move date+1.1% vs SPY3d+18.1%5d+19.0%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ABUS calls or request research access.

More ABUS calls Browse calls Request research access